Women's Health

Organon is looking for a new CEO after an internal investigation uncovered “improper wholesaler sales practices” relating to its Nexplanon implant. The firm will not revise any previously issued financial statements, despite saying that the tactics helped meet revenue expectations.

Strides and Incepta’s partnership on the first generic injectable contraceptive marks a leap forward for many women in Africa to take control of their reproductive rights.

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.

In an at times incendiary letter, Republican senators have urged the FDA and HHS to suspend approval of a new generic version of the abortion pill mifepristone, citing safety concerns and ongoing federal reviews.

Investors and healthcare philanthropists have launched a new women’s health fund – aiming to be the largest of its kind – with an ambitious goal to not just finance innovation, but to build a sustainable market around it.

The company’s approach leverages mPGES-1 inhibition to target both inflammation-related pain and lesion load. It is moving into a Phase II trial.

Results of survey of 986 oral contraceptive users 15 to 45 years old published online in JAMA Network Open show OTC access drove a 31.8 percentage-point increase in women shifting from no contraceptive method to an effective method.

Launching Heather’s UTI Defense, firm partners with Oxford University in clinical trial comparing its supplement head-to-head with D-mannose, most commonly available dietary ingredient for UTI prevention

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.

Co-founders name their company for their grandmothers – Opal, a Texan rancher, and Joy, a New Zealand artist – to symbolize strength and creativity. Their brand’s premium, ethical ingredients and formulations were developed by a female women’s health doctor.

“Women’s health continues to be ignored, underfunded, and sidelined. Too many women still die from preventable causes or live in poor health. That must change,” says Bill Gates.

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.